A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Early Breast Cancer
Interventions: DRUG: Giredestrant|DRUG: Endocrine Therapy of Physician's Choice|DRUG: LHRH Agonist|DRUG: Abemaciclib
Sponsor: Hoffmann-La Roche